Posted by Michael Wonder on 01 Sep 2023
Efgartigimod for the treatment of patients with generalised myasthenia gravis
1 September 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of efgartigimod in the NHS in England.
Efgartigimod is not recommended when used as an addition to standard care for the treatment of adults with generalised myasthenia gravis who have tested positive for anti-acetylcholine receptor antibodies.
